Abstract: The invention relates to a composition which is oxidatively effective on keratin-containing fibers, in particular human hair, and which, besides at least one oxidizing agent, comprises an active ingredient combination of (a) a selected cationic polymer, (b) at least one mono- or di(C.sub.8- to C.sub.30)-alkylammonium salt and (c) at least one quaternary ammonium compound which carries at least one selected group on the quaternized nitrogen atom, and to a method of reshaping keratin-containing fibers, in which this composition is used, and to the use of this composition for fixing in the course of hair reshaping. The reshaping is improved through these compositions and the fiber receives excellent care and structure retention.

Abstract: The present invention provides a method for preparing a solubilized composition containing an oil-soluble substance having both acid and heat resistance, including: the step of dissolving an oil-soluble substance and two or three emulsifiers selected from (1) an emulsifier E1 comprising an ester of a fatty acid having an HLB of not less than 10 and not more than 14 carbon atoms with a polyglycerol having a polymerization degree of not less than 3, (2) an emulsifier E2 comprising an ester of a fatty acid having an HLB of not less than 10 and not more than 14 carbon atoms with sucrose, or (3) an emulsifier E3 comprising lecithin in which phosphatidylcholine accounts for not less than 50% and/or lysolecithin in which lysophosphatidylcholine accounts for not less than 50% of a phospholipid content in (a) ethanol or (b) a mixed solvent of ethanol with at least one selected from the group consisting of acetone, hexane, and ethyl acetate to prepare a transparent solution; and the step of distilling the solvent of

Abstract: A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin or its HCl salt, which is subject to intra-molecular cyclization, which formulation includes a tablet core containing one or more fillers, and other conventional excipients, which tablet core includes a coating thereon which may include two or more layers, at least one layer of which is an inner seal coat layer which is formed of one or more coating polymers, a second layer of which is formed of medicament which is the DPP4-inhibitor and one or more coating polymers, and an optional, but preferable third outer protective layer which is formed of one or more coating polymers. A method for forming the coated tablet is also provided.

Abstract: One aspect of the invention relates to a pharmaceutical dosage unit for sublingual, buccal, pulmonary or oral administration, said dosage unit having a weight of 20-500 mg and comprising 1-80 wt. % of a microgranulate that is distributed throughout a solid hydrophilic matrix; said microgranulate being characterized in that it: has a volume weighted average diameter of 5-100 m; contains at least 0.01 wt. %, preferably at least 0.1 wt. % of one or more water-insoluble pharmaceutically active substances; contains at least 10 wt. %, preferably at least 20 wt. % of an emulsifier component; and is capable of forming a micro-emulsion upon contact with saliva or water. The dosage units of the present invention achieve the inherent benefits of oral delivery while at the same time realizing a high transmucosal absorption rate of the cannabinoids contained therein.

Abstract: Provided is an oil-in-water emulsion composition which, while having a fresh feel without stickiness when used, has a skin unevenness correction effect and persistence thereof, and provides excellent smoothness, moisture and shininess, and feeling of tension. The oil-in-water emulsion composition is characterized by containing, in a specific ratio: (A) a non-emulsifying cross-linked polymethyl siloxane, which contains (a1) a dimethicone crosspolymer and (a2) a non-emulsifying cross-linked polymethyl siloxane other than a dimethicone crosspolymer; (B) an associative thickener; (C) a polyether-modified silicone; (D) a silicone oil; and (E) water in a specific ratio. The oil-in-water emulsion composition is further characterized in that the mass ratio ((a2)/(a1)) of (a2) the non-emulsifying cross-linked polymethyl siloxane other than a dimethicone crosspolymer to (a1) the dimethicone crosspolymer falls within a range of 0.1 to 2.5.

Abstract: Disclosed herein is a fragrant formulation comprising a fragrant composition, and an alkyl ketal ester. Disclosed herein too are methods for manufacturing the fragrant formulation.

Abstract: The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a food, food with nutrient function claims, food for specified health uses, dietary supplement, nutritional product, animal drug, drink, feed, pet food, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like, which contain the composition.

Abstract: Temperature-insensitive calcium phosphate cements and methods of using the same are provided. Aspects of the cements include a dry component having fine and coarse calcium phosphate particulate reactants and a setting fluid which includes a cellulose. The dry component and setting fluid may be combined over a broad temperature range to produce a flowable composition. The resultant flowable composition finds use in a variety of different applications, including the repair of hard tissue defects, e.g., bone defects such as fractures.

Abstract: A method of a forming a hollow, drug-eluting medical device includes providing composite member having an outer member and a core member disposed within a lumen of the outer member. The composite member is shaped into a pattern. Openings are formed through the outer member of the composite member. The composite member is processed to remove the core member from the lumen of the outer member without harming the outer member, leaving a hollow tubular member already formed into the desired pattern. The lumen of the outer member is filled with a therapeutic substance.

Abstract: Disclosed herein are ionic liquid compositions comprising active pharmaceutical, biological, and nutritional compounds, and methods of use. Further disclosed are compositions of matter including liquid ion pairs alone or in solution and their use; compositions of ionic liquids that are ‘solvated,’ for example, ‘hydrated’ and their uses.

Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Abstract: The present invention is directed to dosage forms that can be used in therapeutic methods involving the oral co-administration of a combination of at least two drugs, one of which impairs gastrointestinal absorption and one of which does not. The dosage forms are designed so that the drug impairing absorption is not released into the gastrointestinal tract of a patient until after the drugs that do not impair absorption have been released and substantially absorbed. The invention may be used in treatment of migraine using a combination of triptans and NSAIDs or in the treatment of pain using a combination of NSAIDs and opioid analgesics.

Abstract: The invention is related to a disposable contact lens comprising a top coating which is made of a hydrophilic polymeric material including dangling hydrophilic polymer chains covalently linked to the hydrophilic polymeric material through oligo-caprolactone linkages susceptible to enzymatic degradation in the eyes. The top coating is stable to lens processing/storage and confers lubricity to the lens. However, it slowly is degraded during the lens wear due to the action of enzymes (e.g., Lipase) in tear film. The loss in lubricity will be experienced as a drop in comfort for the lens wearer and thereby serves as the built-in compliance features of the disposable contact lens.

Abstract: The invention relates to a method for producing a medicament containing tadalafil. In said method, tadalafil is mixed with suitable adjuvants and is heated to a temperature of about 100° C. to about 200° C., preferably about 150° C. to about 200° C., especially about 200° C.

Abstract: The present invention relates to a skin care composition comprising at least two oil phases dispersed in a continuous aqueous phase comprising a thickening agent, wherein a first oil phase of the oil phases has different composition from the other oil phase, and wherein the composition contains an emulsifier no more than 1.0%. The present invention also relates to a method of preparing a skin care composition comprising dispersing a first oil phase in a continuous aqueous phase comprising a thickening agent; and dispersing a second oil phase in the continuous aqueous phase; wherein composition of said first oil phase differs from composition of said second oil phase, and wherein the composition contains an emulsifier no more than 1.0%.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse.

Abstract: The present invention relates to flavor oils including mint-, fruit- and spice-type flavors that are specially processed to substantially eliminate low-molecular weight sulfur compounds, in particular dimethyl sulfoxide (DMSO), which has been found to be the main precursor of malodorous species such as dimethyl sulfide and methyl mercaptan. These malodorous species are produced via oxidation-reduction reactions involving such sulfur-containing compounds present in flavor oils. A preferred processing method is an aqueous-washing process, which has advantages of being simple, inexpensive and easy to implement while importantly avoiding the problems of typical processes including non-selective removal of desirable components and subjecting the flavor oils to extreme conditions that may destroy other components and result in undesirable changes in flavor or odor character.

Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2, 4, 7-trioxo-3, 4, 6, 7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Abstract: A chewable tablet comprising Cefixime having a mean particle size between 20? and 120? wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20? and 120?, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.

Abstract: The invention relates to implants which are based on a biodegradable thixotropic compound having pseudoplastic properties and which can be injected subcutaneously or intradermally into the fibrous tissue. The inventive implant comprises microparticles of at least one biocompatible ceramic compound which are suspended in a vector fluid containing at least one hyaluronic acid-based compound and at least one biodegradable thixotropic compound having pseudoplastic properties. The invention also relates to a kit for the extemporaneous use of such implants, the production of said implants and the use thereof in order to fill wrinkles and/or fine lines and/or cutaneous depressions and/or scars.